PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Predicting Protein Crystal Candidates
October 2014
Drug Discovery: Finding Druggable Targets
October 2013
Membrane Proteome: Unveiling the Human α-helical Membrane Proteome
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
Infectious Diseases: Targeting Meningitis
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Targeting Enzyme Function with Structural Genomics
July 2012
Disordered Proteins
February 2012
The cancer kinome
April 2010
Learning from failure
December 2009
Dealing with difficult families
February 2009

Technology Topics Target Selection

Infectious Diseases: Targeting Meningitis

SBKB [doi:10.1038/sbkb.2012.140]
Technical Highlight - May 2013
Short description: Screens with substrates and inhibitors, followed by molecular modeling, reveal details of an enzyme's ligand binding specificity.

Model of NmAPN with its most potent inhibitor, with interactions indicated in green. Figure courtesy of Artur Mucha.

Bacterial pathogens that plague the human population are becoming increasingly resistant to broad-spectrum antibiotics. In order to develop new antibiotics, a clear understanding of the mode of action of potential bacterial targets is necessary, including knowledge of the contacts between enzymes and their substrates, to design drugs that thwart those interactions and stop the pathogen in its tracks. Mucha and colleagues (PSI MCSG) have now performed such an analysis for the alanine aminopeptidase of Neisseria meningitides (NmAPN) —a pathogen that can cause meningitis, a disease still prevalent in the developing world.

First, the authors determined the substrate specificity of NmAPN. As this enzyme catalyzes the removal of N-terminal amino acids from substrate proteins, a library of fluorogenic substrates was used to measure hydrolysis rates. The analysis revealed that the enzyme prefers substrates with bulky, hydrophobic side chains: L-homoarginine, L-arginine and L-alanine were the top three substrates. Substrate preferences were notably different than those of human APN, a dissimilarity that could be important in the design of drug inhibitors specific to the bacterial enzyme.

Next, a set of six inhibitors was tested; these were organophosphorus compounds derived from arginine and homophenylalanine, which yielded inhibition constants ranging from 0.05μM to 2.5μM. The researchers then modeled the NmAPN–inhibitor complexes, based on known structures of native NmAPN and Plasmodium falciparum APN in complex with an inhibitor. This analysis pinpointed the specific interactions responsible for tighter binding and thus greater inhibitory activity of the best inhibitor for NmAPN. This integrated work should aid in the treatment of meningitis through the design of inhibitors of NmAPN with high affinity and specificity.

Irene Kaganman

References

  1. E. Węglarz-Tomczak et al. An integrated approach to the ligand binding specificity of Neisseria meningitidis M1 alanine aminopeptidase by fluorogenic substrate profiling, inhibitory studies and molecular modeling.
    Biochimie. 95, 419-428 (2013). doi:10.1016/j.biochi.2012.10.018

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health